GI Dynamics is Now Morphic Medical. Learn More.

To assess the safety of the DJBL and to evaluate its potential to affect glycemic control beneficially in subjects with T2DM who were not morbidly obese.

The purpose of this study was to evaluate the effect of the duodenal–jejunal bypass liner (DJBL), a 60-cm, impermeable fluoropolymer liner anchored in the duodenum to create a duodenal–jejunal bypass, on metabolic parameters in obese subjects with type 2 diabetes.

To evaluate safety, weight loss, and cardiometabolic changes in obese subjects implanted with the duodenal-jejunal bypass liner (DJBL) for 1 year.

This is an interim report of an ongoing one year study. In a prospective, randomized, diet controlled, multicentre study, 77 subjects were included, 38 device and 39 diet controls, treatment 6 months with 6 month follow-up.

To investigate glycemic control and the underlying mechanisms of the Duodenal Jejunal Bypass Liner (DJBL).

The duodenal-jejunal bypass liner has been evaluated in clinical studies of patients with morbid obesity, where it has been shown to result in substantial weight loss after 12 or 24 weeks [3,4].

The aim of the present study was to evaluate the clinical effects and safety of the duodenal-jejunal bypass liner combined with a restrictor orifice (flow restrictor).

This 12-week, open-label, randomized trial investigated the use of the DJBL versus a sham upper endoscopy for weight loss before bariatric surgery.

Obese T2DM subjects were randomized to receive a DJBL (n ¼ 12) or sham endoscopy (n ¼ 6) in a 24-week study, extended up to 52 weeks.

To investigate the contributions of two surgical gut manipulations—exclusion of the proximal intestine from alimentary flow and exposure of the jejunum to partially digested nutrients—to body weight regulation and metabolism, we have developed a rat model of an investigational device, the...